Montelukast Asthmapharma

Montelukast, the active ingredient in Montelukast Asthmapharma, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma and allergic rhinitis in patients requiring chronic management by blocking cysteinyl leukotriene receptors, thereby reducing bronchoconstriction and airway inflammation, and improving symptom control.

GNH USA supplies Montelukast Asthmapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with reliable quality assurance and regulatory compliance, and on‑time delivery to meet global healthcare needs.

Montelukast, a leukotriene receptor antagonist, is used to manage respiratory allergic conditions. - Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes. - Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Montelukast may cause adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate pain in the head. - Abdominal pain: discomfort or cramps in the stomach area. - Cough: persistent dry cough. - Nausea: feeling of sickness or urge to vomit. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Allergic reactions: rash, swelling, angioedema or anaphylaxis. - Neuropsychiatric events: mood changes, depression or suicidal thoughts. - Hepatic enzyme elevation: increased liver function test results. - Blood disorders: eosinophilia, neutropenia or thrombocytopenia.

Before prescribing Montelukast, clinicians should consider several precautionary measures. - Assess asthma control: ensure patient’s asthma is stable before initiating therapy. - Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be required in liver disease. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Not for acute asthma attacks: should not replace rescue bronchodilators. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: enzyme induction may reduce montelukast plasma levels. - Rifampin: strong CYP3A4 inducer can lower drug exposure. - Ketoconazole: potent CYP3A4 inhibitor may increase montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Oral contraceptives: montelukast may reduce hormonal efficacy, consider alternative contraception. - Beta‑agonists: monitor for additive bronchodilator effects.